Prescription medicine
Netarsudil Brand names: Rhopressa
Netarsudil (Rhopressa) is a prescription medicine with an FDA approval on record since 2017. No generic is listed; pharmacies paid $131.68 per mL (Rhopressa 0.02% eye solution) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the netarsudil FDA label on DailyMed (effective January 20, 2026, Alcon Laboratories, Inc.); the NDA 208254 record on Drugs@FDA; every netarsudil label on DailyMed.
Highlights of the record
FDA label of January 20, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageRHOPRESSA is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Forms and strengths
- 0.2 mg/ml
Solution/ drops.
On the market
- Earliest approval on file
- December 18, 2017 Rhopressa, Alcon Labs Inc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- March 14, 2034 Rhopressa solution/drops; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $131.68 per mL Rhopressa 0.02% eye solution
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 1,940 through July 30, 2026
What is netarsudil used for?
From the label: indications and usageRHOPRESSA is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. RHOPRESSA ® is a Rho kinase inhibitor indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Conditions named in the indications of netarsudil's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Rho Kinase Inhibitor.
Source: FDA drug label (Rhopressa), Alcon Laboratories, Inc., effective January 20, 2026 (SPL set 7d4f0e3a-5b86-4c43-982a-813b22ae7e22), via openFDA; the full label on DailyMed
Is there a generic for netarsudil (Rhopressa)?
No generic netarsudil is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 15 patents for Rhopressa solution/drops: the compound patent runs to March 14, 2034. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2017 earliest approval on file
- 2034 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for netarsudil (Rhopressa)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $131.68 per mL (Rhopressa 0.02% eye solution), up 3% from $128.05 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Rhopressa 0.02% eye solution (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Rhopressa 0.02% eye solution | Brand | $131.68 per mL | n/a | +3% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for netarsudil?
The FDA Adverse Event Reporting System holds 1,940 reports that list netarsudil among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 60 are coded as a death and 103 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other rho kinase inhibitors
- the pharmacologic class, with prices and generics
- Netarsudil side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other